These data open new perspectives for the molecular understanding of juvenile steatosis, the analysis of Kit function during liver development and support the need to follow-up hepatic function in patients during anti-cancer treatment with the inhibitor of KIT activity, STI-571, reported to affect the weight and the viability of rat neonates [61]. Here, KIT is linked to steatosis.